急性間歇性紫質症市場規模、佔有率和成長分析（按診斷、治療方法、最終用戶和地區分類）—產業預測，2026-2033年

預計到 2024 年，急性間歇性紫質症(AIP) 市場規模將達到 44.5 億美元，到 2025 年將達到 45.9 億美元，到 2033 年將達到 58.6 億美元，在預測期（2026-2033 年）內複合成長率為 3.1%。

急性間歇性紫質症(AIP) 市場正經歷顯著成長，這主要得益於公眾意識的提高、診斷技術的進步以及創新療法的開發。 AIP 是一種罕見的遺傳性疾病，會影響血紅素的生成。由於基因檢測等診斷工具的改進，AIP 已引起醫療保健領域的廣泛關注，這些工具能夠早期準確地識別患者。儘管製藥業的研發工作已催生新的治療方案，但加強病患教育對於有效控制症狀至關重要。儘管取得了這些進展，但仍存在一些挑戰，例如診斷不足和治療選擇有限。醫療保健提供者、研究人員和製藥公司之間的合作對於克服這些複雜挑戰並充分發揮 AIP 市場的潛力至關重要。

急性間歇性紫質症市場區隔分析

急性間歇性紫質症市場促進因素

對先進診斷技術的日益重視顯著提高了急性間歇性紫質症症 (AIP) 的識別率，從而能夠及時進行干預和管理。此外，諸如血紅素輸注和創新RNA干擾(RNAi) 療法（如 givosiran）等新型治療方案的開發，為控制急性發作和長期症狀提供了更有效的策略。這些改進的診斷技術和新型治療方法的結合正在推動 AIP 市場的發展，幫助患者獲得更好的護理和更好的健康結果。這些進步的整合正在持續改變疾病患者的治療格局。

限制急性間歇性紫質症市場的因素

急性間歇性紫質症市場面臨的一大挑戰是疾病的診斷不足，而其罕見性和症狀的複雜性加劇了這個問題。這種複雜性常常導致患者被延誤診斷或漏診。此外，治療選擇有限，主要著重於緩解症狀而非提供根治性治療方法，這限制了治療環境。這些診斷難題，加上治療選擇的匱乏，會阻礙市場成長，並使患者無法及時獲得有效的治療。應對這些挑戰對於改善治療效果和擴大市場潛力至關重要。

急性間歇性紫質症市場趨勢

急性間歇性紫質症(AIP) 市場正經歷顯著成長，這主要得益於基因檢測技術的進步，使得患者診斷更加精準快速。精準醫療的轉型也得益於創新治療方法的出現，例如RNA干擾(RNAi) 療法，包括 givosiran 等藥物。這些治療方法特異性針對 AIP 的遺傳基礎。這些進展不僅提高了治療效果，也改善了患者的預後，從而擴大了患者群體並推動了市場需求。隨著人們對 AIP 的認知和了解不斷加深，其診斷和治療模式必將迎來蓬勃發展。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

全球急性間歇性紫質症市場規模（按診斷和複合年成長率分類）（2026-2033 年）

• 血液檢查
• 尿液檢查
• DNA檢測
• 血清檢測

全球急性間歇性紫質症市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 促性腺激素分泌釋放激素類似物
• 預防性血紅素輸注

全球急性間歇性紫質症市場規模（以最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 研究中心

全球急性間歇性紫質症市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Alnylam Pharmaceuticals（United States）
• Recordati SpA（Italy）
• Sanofi SA（France）
• BioMarin Pharmaceutical Inc.（United States）
• Siemens Healthineers AG（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Ipsen Pharma（France）
• Clinuvel Pharmaceuticals Ltd（Australia）
• Quest Diagnostics（United States）
• Mayo Clinic Laboratories（United States）
• Bachem Holding AG（Switzerland）
• Grifols, SA（Spain）
• Ferring Pharmaceuticals（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Moderna, Inc.（United States）
• Dicerna Pharmaceuticals, Inc.（United States）
• Zambon SpA（Italy）
• Luitpold Pharmaceuticals, Inc.（United States）
• Vifor Pharma（Switzerland）

結論與建議

Acute Intermittent Porphyria Market size was valued at USD 4.45 Billion in 2024 and is poised to grow from USD 4.59 Billion in 2025 to USD 5.86 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth, driven by increased awareness, advancements in diagnostic techniques, and innovative treatment developments. As a rare genetic disorder affecting heme production, AIP is garnering attention in the healthcare sector, thanks in part to improved diagnostic tools like genetic testing that enable earlier and more accurate identification of patients. The pharmaceutical industry's commitment to research and development is fostering new therapeutic options, while enhanced patient education is crucial for effective symptom management. Despite these advancements, challenges remain, including underdiagnosis and a limited range of treatment alternatives. A collaborative approach among healthcare providers, researchers, and pharmaceutical companies is essential to navigate the complexities and fully realize the potential of the AIP market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segments Analysis

Global Acute Intermittent Porphyria Market is segmented by Diagnosis, Treatment, End Users and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, DNA Test and Serum Test. Based on Treatment, the market is segmented into Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions. Based on End Users, the market is segmented into Hospitals, Clinics and Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Acute Intermittent Porphyria Market

The growing emphasis on advanced diagnostic techniques has significantly improved the identification of Acute Intermittent Porphyria (AIP) cases, enabling timely intervention and management. Furthermore, the development of new treatment options, such as hematin infusions and innovative RNA interference (RNAi) therapies like givosiran, provides more effective strategies for managing acute episodes and long-term symptom control. This combination of enhanced detection and novel therapeutic approaches is driving the AIP market forward, ensuring patients receive better care and improved health outcomes. The integration of these advancements continues to transform the landscape for those affected by this condition.

Restraints in the Acute Intermittent Porphyria Market

A significant challenge in the Acute Intermittent Porphyria market is the underdiagnosis of the condition, which is exacerbated by its rarity and the intricate nature of its symptoms. This complexity often results in delays or missed diagnoses for those affected. Furthermore, the treatment landscape is constrained by the limited options available, primarily focusing on alleviating symptoms rather than offering a definitive cure. This combination of diagnostic difficulties and restricted therapeutic alternatives hinders market growth and can prevent patients from receiving timely and effective care. Addressing these issues is essential for improving outcomes and expanding market potential.

Market Trends of the Acute Intermittent Porphyria Market

The Acute Intermittent Porphyria (AIP) market is experiencing significant growth driven by advances in genetic testing technologies, which facilitate more accurate and timely diagnoses for patients. This shift towards precision medicine is bolstered by the emergence of innovative treatments such as RNA interference (RNAi) therapies, including medications like givosiran, that specifically target the genetic basis of AIP. These developments not only enhance therapeutic efficacy but also improve patient outcomes, thereby expanding the patient pool and driving demand in the market. As awareness and understanding of AIP increase, the landscape for diagnosis and treatment is poised for robust evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Acute Intermittent Porphyria Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Test
• Urine Test
• DNA Test
• Serum Test

Global Acute Intermittent Porphyria Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

Global Acute Intermittent Porphyria Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Centers

Global Acute Intermittent Porphyria Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, End Users)
  • US
  • Canada
• Europe (Diagnosis, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clinuvel Pharmaceuticals Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luitpold Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vifor Pharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations